Amendment No. 4 to License Agreement between the Regents of The University of Michigan and OncoMed Pharmaceuticals, Inc.
Exhibit 10.4(E)
Amendment No. 4 to License Agreement between
the Regents of The University of Michigan and
OncoMed Pharmaceuticals, Inc.
The License Agreement dated as of January 5, 2001, as heretofore amended (the “License Agreement”), between the REGENTS OF THE UNIVERSITY OF MICHIGAN, a constitutional corporation of the State of Michigan (“Michigan”) and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation having offices at 000 X. Xxxxxxx Xxxx, Xxxxxxxx Xxxx, XX 00000 (“Licensee”), is hereby amended as follows:
1. Without limiting the generality of the definition of “Licensed Patent(s)” set forth in Section 30.4 of the License Agreement, Licensed Patents comprise the list of patent applications, disclosures and XXX files set forth on Attachment B hereto, and Attachment B referenced in Section 30.4 of the License Agreement is hereby amended by substituting in full Attachment B hereto.
2. Michigan hereby deems any and all of the support obligations of Licensee of continued research in the laboratories of Xx. Xxxxx and Xx. Xxxxxx relating to the Licensed Field as described in Section 4.6 of the License fully satisfied, and Michigan hereby agrees that Licensee is relieved of any and all obligations to provide any payment pursuant to Section 4 of Amendment No. 1 to the License Agreement for the twelve-month period from July 21, 2004 and for any twelve-month period thereafter.
3. The License Agreement, as amended by this Amendment No. 4, shall otherwise remain unaltered and in full force and effect.
4. This Amendment No. 4 may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have executed this Amendment No. 4 by their duly authorized officers or representatives effective as of December 12, 2005.
| ONCOMED PHARMACEUTICALS, INC. |
THE REGENTS OF THE UNIVERSITY OF MICHIGAN | |||||||
| By | /s/ Xxxxx X. Xxxxx | By: | /s/ Xxxxxxx X. Xxxxxx | |||||
| Xxxxx X. Xxxxx, M.D., Ph.D. | Name: | Xxxxxxx X. Xxxxxx | ||||||
| Chief Executive Officer | Title: | Executive Director, UM Technology Transfer | ||||||
| File # |
Lic Rep |
Title |
Name | Department | Filing Date | Appl # | Country | Application Type | Patent Status | |||||||||||
| 3223 |
Xxxxx Xxxxx | Methods for Identifying Mouse Breast Cancer Stem Cells | Xxxxxxx X. Xxxxxx | Internal Medicine Department | 10/31/2005 | 60/731,470 | US | PRV - Provisional | Pending | |||||||||||
| 3222 |
Xxxxx Xxxxx | Methods for Treating and Diagnosing Cancer: Array Analysis of Colin and Head and Neck Cancer Stem Cells – This is a Marker | Xxxxxxx X. Xxxxxx | Internal Medicine Department | 10/31/2005 | 60/731,465 | US | PRV - Provisional | Pending | |||||||||||
| 3221 |
Xxxxx Xxxxx | Methods for Treating and Diagnosing Cancer: Array Analysis of Colon and Head and Neck Cancer Stem Cells | Xxxxxxx X. Xxxxxx | Internal Medicine Department | 10/31/2005 | 60/731,469 | US | PRV - Provisional | Pending | |||||||||||
| 3211 |
Xxxxx Xxxxx | Methods for Treating and Diagnosing Head and Neck Cancer | Xxxxxxx X. Xxxxxx | Internal Medicine Department | 10/31/2005 | 60/731,279 | US | PRV - Provisional | Pending | |||||||||||
| 3097 |
Xxxxx Xxxxx | Methods for Treating and Diagnosing Cancer | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
6/13/2005 6/13/2005 |
|
60/690,003 60/690,001 |
US US |
PRV - Provisional | Pending Pending | |||||||||
| 2705 |
Xxxxx Xxxxx | Cancer Stem Cells and Notch | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
02/03/2004 02/03/2005 02/03/2005 |
|
60/541,527 11/050,282 PCT/US05/03419 |
US US PCT |
PRV - Provisional ORD - Ordinary PCT - Patent Cooperation Treaty |
Pending Pending Pending | |||||||||
| 2629 |
Xxxxx Xxxxx | Genes Expressed by Cancer Stem Cells | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
06/09/2003 06/09/2003 06/09/2004 06/09/2004 |
|
60/477,235 60/477,228 10/864,207 PCT/US04/18266 |
US US US PCT |
PRV - Provisional PRV - Provisional ORD - Ordinary PCT - Patent Cooperation Treaty |
Converted Converted Pending Pending | |||||||||
| 2237 |
Xxxxx Xxxxx | Breast Cancer Stem Cells and Notch Signaling | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
12/07/2001 12/06/2002 10/29/2004 12/06/2002 12/06/2002 12/06/2002 12/06/2002 |
|
60/338,358 PCT/US02/39191 10/497,791 2002364537 2469204 02799914.3 2003-551505 |
US PCT US AU CA EP JP |
PRV - Provisional PCT - Patent Cooperation Treaty 371 - US from PCT as Foreign PCT - Nat. Stg. PCT - Nat. Stg. PCT - Nat. Stg. PCT - Nat. Stg. |
Converted Nationalized Pending Pending Pending Pending Pending | |||||||||
| 1980 |
Xxxxx Xxxxx | An Efficient Xenograft Human Epithelial Cancer Model | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
10/13/2000 08/02/2001 08/01/2001 |
|
60/240,317 PCT/US01/24243 09/920,517 |
US PCT US |
PRV - Provisional PCT - Patent Cooperation Treaty ORD - Ordinary |
Converted Nationalized Allowed | |||||||||
| 1876 |
Xxxxx Xxxxx | Purification of a Breast Cancer Tumor Initiating (Stem) Cell | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
08/02/2001 08/01/2001 |
|
PCT/US01/24243 09/920,517 |
PCT US |
PCT - Patent Cooperation Treaty ORD - Ordinary |
Nationalized Allowed | |||||||||
| 1819c1 |
Xxxxx Xxxxx | Isolation and Use of Solid Tumor Stem Cells | Xxxxxxx X. Xxxxxx | Internal Medicine | 1/31/2003 | 10/343,692 | US | 371 - US from PCT as Foreign | Pending | |||||||||||
| 1819 |
Xxxxx Xxxxx | Cancer Stem Cells | Xxxxxxx X. Xxxxxx | Internal Medicine |
|
08/03/2000 10/13/2000 08/02/2001 08/01/2001 08/02/2001 08/02/2001 08/02/2001 08/02/2001 01/31/2003 06/10/2005 06/10/2005 00/00/0000 00/00/0000 |
|
60/222,794 60/240,317 PCT/US01/24243 09/920,517 2001278134 2417909 01956101.8 2002-517738 10/343,692 11/150,073 11/150,524 |
US US PCT US AU CA EP JP US US US US US |
PRV - Provisional PRV - Provisional PCT - Patent Cooperation Treaty ORD - Ordinary PCT - Nat. Stg. PCT - Nat. Stg. PCT - Nat. Stg. PCT - Nat. Stg. 371 - US from PCT as Foreign DIV - Divisional DIV - Divisional DIV - Divisional DIV - Divisional |
Converted Converted Nationalized Allowed Pending Pending Pending Pending Pending Pending Pending Not Yet Filed Not Yet Filed | |||||||||
